Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients
| Autor: | Nicolas Picard, Amany Mohamad Ali, Ehab S. El Desoky, Jean-Baptiste Woillard, Pierre Marquet, Mohammad Salem Hareedy, Romany Helmy Thabet |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Adolescent Genotype Single-nucleotide polymorphism Neutropenia Polymorphism Single Nucleotide hemic and lymphatic diseases Genetics Humans Medicine Child Childhood Acute Lymphoblastic Leukemia Pharmacology Leukopenia Mercaptopurine business.industry Proportional hazards model Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Hematologic Diseases Child Preschool Immunology Molecular Medicine Egypt Female ITPA medicine.symptom business Pharmacogenetics Signal Transduction medicine.drug |
| Zdroj: | Pharmacogenomics. 16:1119-1134 |
| ISSN: | 1744-8042 1462-2416 |
| DOI: | 10.2217/pgs.15.62 |
| Popis: | Aim: We investigated the associations between variants in genes coding for enzymes and transporters related to the 6-mercaptopurine pathway and clinical outcomes in pediatric patients with acute lymphoblastic leukemia. Materials & methods: Statistical association between gender, age and genotypes of selected SNPs, and the risks of hematological toxicity and relapse were investigated using a Cox proportional hazard model in 70 acute lymphoblastic leukemia patients from upper Egypt. Results: We found significant associations between ITPA, IMPDH1, SLC29A1, SLC28A2, SLC28A3 and ABCC4 SNPs and one or more of the hematological toxicity manifestations (neutropenia, agranulocytosis and leukopenia); age was significantly related to relapse. Conclusion: Genetic polymorphisms in enzymes and transporters involved in the 6-mercaptopurine pathway should be considered during its use to avoid hematological toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|